“I Just Wanted Nothing More Than to Get in a Real Shower”: Patient Experience of the Inpatient Wait for a Heart Transplant

Salerno, Christopher T.; Pack, Quinn R.; Jurkowski, Briana; McAnally, Kyle; DeJong, Christene; Ahmad, Faraz; Lagu, Tara

doi:10.1016/j.cardfail.2023.05.020

Cited by 3 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite notable advancements in surgical techniques, tissue engineering, and immunosuppression protocols, the persistent shortage of donor organs and viable treatment options remains a critical challenge [22][23][24]. This scarcity not only prolongs waiting periods for patients but also exacerbates their medical conditions, leading to uncertainty and frequently unfavorable prognoses and outcomes [25,26]. Moreover, the intricate interplay of immunological factors presents obstacles, increasing the risk of graft rejection and requiring long-term immunosuppressive regimens that generate well-known adverse effects [27,28].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Engraftment and Safety of Human Umbilical Di-Chimeric Cell (HUDC) Therapy after Systemic Intraosseous Administration in an Experimental Model

Siemionow,

Chambily,

Brodowska

2024

Biomedicines

View full text Add to dashboard Cite

Cell-based therapies hold promise for novel therapeutic strategies in regenerative medicine. We previously characterized in vitro human umbilical di-chimeric cells (HUDCs) created via the ex vivo fusion of human umbilical cord blood (UCB) cells derived from two unrelated donors. In this in vivo study, we assessed HUDC safety and biodistribution in the NOD SCID mouse model at 90 days following the systemic intraosseous administration of HUDCs. Twelve NOD SCID mice (n = 6/group) received intraosseous injection of donor UCB cells (3.0 × 106) in Group 1, or HUDCs (3.0 × 106) in Group 2, without immunosuppression. Flow cytometry assessed hematopoietic cell surface markers in peripheral blood and the presence of HLA-ABC class I antigens in lymphoid and non-lymphoid organs. HUDC safety was assessed by weekly evaluations, magnetic resonance imaging (MRI), and at autopsy for tumorigenicity. At 90 days after intraosseous cell administration, the comparable expression of HLA-ABC class I antigens in selected organs was found in UCB control and HUDC therapy groups. MRI and autopsy confirmed safety by no signs of tumor growth. This study confirmed HUDC biodistribution to selected lymphoid organs following intraosseous administration, without immunosuppression. These data introduce HUDCs as a novel promising approach for immunomodulation in transplantation.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Engraftment and Safety of Human Umbilical Di-Chimeric Cell (HUDC) Therapy after Systemic Intraosseous Administration in an Experimental Model

Siemionow,

Chambily,

Brodowska

2024

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Interviewees described that access to basic comforts, such as good food, being allowed to shower, and access to the outdoors played a pivotal role in their overall well-being during hospitalization. 1 Although many appreciated the clear communication they received from health care staff, many wanted more information and clearer expectations for when and how they would get news.…”

mentioning

confidence: 99%

Both Sides of the Stethoscope

Salerno

2023

Circulation

Self Cite

View full text Add to dashboard Cite

Qualitative interview study of patient-reported symptoms, impacts and treatment goals of patients with obstructive hypertrophic cardiomyopathy

Shore,

Ervin,

Kosa

et al. 2024

BMJ Open

View full text Add to dashboard Cite

ObjectiveHypertrophic cardiomyopathy (HCM), including obstructive HCM (oHCM), is the most common inherited cardiomyopathy causing lifestyle-limiting symptoms. Data are lacking about patients’ perspectives on the daily impact of their symptoms. This qualitative interview study was conducted to better understand patients’ experiences with oHCM.MethodsIn October 2019, telephone interviews were conducted with 20 US adults with oHCM identified by the Hypertrophic Cardiomyopathy Association. Using a semi-structured interview guide, key symptoms, impacts of oHCM and oHCM treatment goals were discussed.ResultsMedian age was 54 years (range 29–78), 55% were women, 85% were white and 15% were Hispanic or Latino. Median time since diagnosis was 3 years. Symptoms included shortness of breath, dizziness/light-headedness, heart palpitations/fluttering (all 95%), fatigue (90%) and chest pain/pressure (80%). All participants reported limitations in physical functioning/activities; most reported additional impacts (emotional stress (80%), fear of dying (55%)). Shortness of breath and fatigue were among their most bothersome symptoms; an effective oHCM treatment would need to improve ≥1 of these symptoms (allowing increased physical/social activity).ConclusionsPatients with oHCM experience a high symptom burden and psychosocial impacts, affecting health status. Improved shortness of breath, fatigue and physical functioning are highly valued by patients and represent important treatment goals.

show abstract

“I Just Wanted Nothing More Than to Get in a Real Shower”: Patient Experience of the Inpatient Wait for a Heart Transplant

Cited by 3 publications

References 6 publications

Efficacy of Engraftment and Safety of Human Umbilical Di-Chimeric Cell (HUDC) Therapy after Systemic Intraosseous Administration in an Experimental Model

Efficacy of Engraftment and Safety of Human Umbilical Di-Chimeric Cell (HUDC) Therapy after Systemic Intraosseous Administration in an Experimental Model

Both Sides of the Stethoscope

Qualitative interview study of patient-reported symptoms, impacts and treatment goals of patients with obstructive hypertrophic cardiomyopathy

Contact Info

Product

Resources

About